In a retrospective analysis, examining GBM tumours from patients treated with signal transduction inhibitors, such as the EGFR TKIs erlotinib or gefitinib, clinical response was highly correlated with co-expression of tumour suppressor PTEN and EGFRvIII in 10%–20% of patients. The gene discussed is EGFR; the disease is neoplasm.